5Bahn Chair RS,Burch HB,Cooper DS,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J].Thyroid,2011,21(6):593-646.
6George J.Kahaly,Luigi Bartalena,et al.The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis:a European perspective[J].Thyroid,2011,21(6):585-591.
7Yamashita S,Amino N,Shong YK.The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines:viewpoints from Japan and Korea[J].Thyroid,2011,21(6):577-580.
8Cooper DS,Doherty GM,Haugen BR,et al.American Thyroid Association(ATA)Guidelines Taskforce on thyroid nodules and differentiated cancer[J].Thyroid,2009,19(11)1167-1214.
9Trdisk F,Tallstedt L,Abraham-Nordling M,et al.Thyroidassociated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131[J].J Clin Endocrinol Metab,2009,94(10):3700-3707.
10Peters H,Fischer C,Bogner U,et al.Radioiodine therapy of Graves' hyperthyroidism:standard vs.calculated 131 iodine activity.Results from aprospective,randomized,multicentre study[J].Eur J Clin Invest,1995,25(3):186-193.
